About StemCyte
StemCyte is a publicly listed company based in Covina (United States) founded in 1997. It operates as an umbilical cord blood stem cell transplantation and therapeutic products company. StemCyte has raised $23.25 million across 6 funding rounds from investors including penbank.com. The company has 43 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its legal entity is STEMCYTE, INC. Its competitors include China Cord Blood, Generate, LaCell, Forever Labs and Provia Labs and 1 more; 3 of its 6 listed competitors have raised funding.
Company details
StemCyte was founded in 1997 and focuses on umbilical cord blood stem cell transplantation and therapeutic products. Cord blood products are delivered to transplant centers for treating blood cancers, immune disorders, and genetic conditions. Storage facilities are maintained in California and Taiwan, with operations spanning the United States, India, and Taiwan. Headquarters are located in Covina, California, supporting global access to these medical resources.
- Headquarters Covina, United States
- Employees 43
- Stage Public
- SectorsHealthcare
- Website stemcyte.com
- Social LinkedIn X Facebook
- Legal Name 4178
- Annual Revenue$368.91 M-3.6as on Dec 31, 2025
- Net Profit-$176.81 M14.03as on Dec 31, 2025
- EBITDA-$161.37 M17.29as on Dec 31, 2025
- Total Equity Funding$23.25M (USD)
in 6 rounds
- Latest Funding Round$2.5M (USD), Debt – Conventional
Nov 2010
- Investors
- Employee Count43
Funding Insights of StemCyte
StemCyte has successfully raised a total of $23.25M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.5 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.25M
- Total Rounds 6
- Last Round Debt – Conventional — $2.5M
- First Round $7.4M
(Mar 2002)
- Investors Count 1
All 6 funding rounds of StemCyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $2.5M | Debt – Conventional | – | – | |
| Oct 2008 | $1.83M | Series B | – | – | – |
| Aug 2006 | $9.05M | Series B | – | – | – |
| Jul 2005 | – | Series A | – | – | – |
| Jun 2002 | $4.98M | Series A | – | – | – |
| Mar 2002 | $7.4M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in StemCyte
StemCyte has secured backing from 1 investor. Prominent investors backing the company include penbank.com.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | penbank.com | - |
Investor details for StemCyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of StemCyte
1 people are tracked at StemCyte (1 in leadership); the tracked headcount is 43.
| Name | Role | Group |
|---|---|---|
Tong-Young Lee | CEO | Leadership |
Complete people profiles for StemCyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of StemCyte
StemCyte is a publicly listed company on the TWSE with ticker symbol 4178 in Taiwan. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Sep 2001
- Listed onTT: 4178
- Listed entity4178
- ISINKYG8477S1084
- Share price17.65 TWD (+1.44% on the day) · 2026-10-14
- Market capitalisation4,015,838,952.00 TWD
- EPS (diluted, trailing year)-0.91 TWD
- Volume (last session)150,310
Financials of StemCyte
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 368.9M TWD | -176.8M TWD | -161.4M TWD |
| 2024 | 382.7M TWD | -205.7M TWD | -195.1M TWD |
| 2023 | 362.8M TWD | -319.8M TWD | -187.8M TWD |
| 2022 | 347.7M TWD | -54.5M TWD | -103.3M TWD |
Detailed financial statements for StemCyte
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of StemCyte
4 dated milestones of StemCyte across 13 years, from founding to its latest funding, stage changes and deals.
- Founded StemCyte is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.4M.
- Funding Latest funding round, Debt – Conventional, of $2.5M.
Competitors of StemCyte
StemCyte has 6 listed competitors in our database, 3 of them funded. They include China Cord Blood, Generate, LaCell, Forever Labs and Provia Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| globalcordbloodcorp.com | 2003 | Hong Kong, China | – | – | Biobanking services for umbilical cord blood stem cells are provided. | |
| generate.com | 1977 | Los Angeles, United States | – | – | Provider of services for the storage of stem cells | |
| lacell-usa.com | 2010 | New Orleans, United States | – | – | Stem Cell Production | |
| foreverlabs.com | 2015 | Detroit, United States | $2.22M | 9 | Stem cells are stored and preserved for future therapeutic applications. | |
| provialabs.com | 2009 | Littleton, United States | $1M | 15 | Stem cell biobanking and manufacturing from children's teeth are provided. | |
| millcreekls.com | 2010 | Rochester, United States | $625,000 | – | Tools and technologies to support the development and application of cellular and biologic therapeutics |
Detailed competitors of StemCyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of StemCyte
The website of StemCyte (stemcyte.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▼ 36.1% vs previous month
Websites whose visitors overlap most with StemCyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cryo-cell.com | 100% | 39.9K | #719,386 | View details | |
| healthgrades.com | 75% | 8.4M | #10,583 | View details | |
bettermedicine.com | bettermedicine.com | 75% | – | #5,224,374 | – |
jeevan.org | jeevan.org | 68% | – | – | – |
parentsguidecordblood.org | parentsguidecordblood.org | 64% | – | #598,338 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for StemCyte
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as StemCyte (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stemcyte
Complete news archive for StemCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about StemCyte
StemCyte was founded in 1997 and raised its 1st funding round 5 years after it was founded.
StemCyte is headquartered in Covina, United States. It is registered at Covina, California, United States.
StemCyte is a funded company, having raised a total of $23.25M across 6 funding rounds to date. The company's 1st funding round was a Series A of $7.4M, raised on Mar 2002.
StemCyte has 43 employees.
StemCyte was founded in 1997 and focuses on umbilical cord blood stem cell transplantation and therapeutic products. Cord blood products are delivered to transplant centers for treating blood cancers, immune disorders, and genetic conditions. Storage facilities are maintained in California and Taiwan, with operations spanning the United States, India, and Taiwan. Headquarters are located in Covina, California, supporting global access to these medical resources.
StemCyte's top competitors include Forever Labs, China Cord Blood and LaCell.
Yes, StemCyte is publicly traded on TWSE under the ticker symbol 4178.
StemCyte has 1 investor. Key investors include penbank.com.
StemCyte operates through Stemcyte, Inc..